1. Genomics to select treatment for patients with metastatic breast cancer
- Author
-
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalves, Thomas Bachelot, Ivan Bieche, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
- Subjects
Multidisciplinary ,Genome, Human ,[SDV]Life Sciences [q-bio] ,Clinical Decision-Making ,DNA Mutational Analysis ,Genes, BRCA2 ,Genes, BRCA1 ,Breast Neoplasms ,Genomics ,Piperazines ,Disease Progression ,Humans ,Phthalazines ,Female ,Neoplasm Metastasis - Abstract
Cancer progression is driven in part by genomic alterations
- Published
- 2022
- Full Text
- View/download PDF